RESUMO
Gram-negative bacteria in the order Rickettsiales have an obligate intracellular growth requirement, and some species cause human diseases such as typhus and spotted fever. The bacteria have evolved a dependence on essential nutrients and metabolites from the host cell as a consequence of extensive genome reduction. However, it remains largely unknown which nutrients they acquire and whether their metabolic dependency can be exploited therapeutically. Here, we describe a genetic rewiring of bacterial isoprenoid biosynthetic pathways in the Rickettsiales that has resulted from reductive genome evolution. Furthermore, we investigated whether the spotted fever group Rickettsia species Rickettsia parkeri scavenges isoprenoid precursors directly from the host. Using targeted mass spectrometry, we found that infection caused decreases in host isoprenoid products and concomitant increases in bacterial isoprenoid metabolites. Additionally, we report that treatment of infected cells with statins, which inhibit host isoprenoid synthesis, prohibited bacterial growth. We show that growth inhibition correlates with changes in bacterial size and shape that mimic those caused by antibiotics that inhibit peptidoglycan biosynthesis, suggesting that statins lead to an inhibition of cell wall synthesis. Altogether, our results describe a potential Achilles' heel of obligate intracellular pathogens that can potentially be exploited with host-targeted therapeutics that interfere with metabolic pathways required for bacterial growth.IMPORTANCE Obligate intracellular pathogens, which include viruses as well as certain bacteria and eukaryotes, are a subset of infectious microbes that are metabolically dependent on and unable to grow outside an infected host cell because they have lost or lack essential biosynthetic pathways. In this study, we describe a metabolic dependency of the bacterial pathogen Rickettsia parkeri on host isoprenoid molecules that are used in the biosynthesis of downstream products, including cholesterol, steroid hormones, and heme. Bacteria make products from isoprenoids, such as an essential lipid carrier for making the bacterial cell wall. We show that bacterial metabolic dependency can represent a potential Achilles' heel and that inhibiting host isoprenoid biosynthesis with the FDA-approved statin class of drugs inhibits bacterial growth by interfering with the integrity of the cell wall. This work supports the potential to treat infections by obligate intracellular pathogens through inhibition of host biosynthetic pathways that are susceptible to parasitism.
Assuntos
Citoplasma/microbiologia , Interações Hospedeiro-Patógeno , Rickettsia/crescimento & desenvolvimento , Rickettsia/metabolismo , Terpenos/metabolismo , Animais , Anticolesterolemiantes/metabolismo , Chlorocebus aethiops , Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo , Terpenos/antagonistas & inibidores , Células VeroRESUMO
Rickettsia quintana grew in a liquid medium consisting of a brain-heart infusion base supplemented with starch and hematin. The growth requirement for hematin could not be substituted by compounds of known catalytic activity for H(2)O(2), viz., catalase, potassium pyruvate, or charcoal, or by the reducing compounds sodium sulfite and sodium thioglycollate. R. quintana was catalase-negative, but no H(2)O(2) production could be demonstrated by the catalase-aminotriazole technique. A minimum inoculum giving 10(5) cells/ml was required to initiate growth. The generation time at 33 C was 10 hr. The temperature range for growth was 28 to 37 C. Growth was enhanced when succinate or glutamate was added as energy source.